Monthly Archives: October 2022

Biochemistry

What is Biochemistry? – Definition, History, Examples, Importance …

Have you ever observed how chemical reactions or processes occur within the human body? How do metabolic activities take place? Yes, you will get to know all these life processes through Biochemistry.

The branch of science dealing with the study of all the life processes such as control and coordination within a living organism is called Biochemistry.

This term was introduced to us by Carl Neuberg, the father of biochemistry in the year 1930. This field combines biology as well as chemistry to study the chemical structure of a living organism. The biochemists get into the investigation of the chemical reactions and combinations which are involved in various processes like reproduction, heredity, metabolism, and growth, thus performing research in different kinds of laboratories.

Introduction to Biochemistry includes wide areas of molecular biology as well as cell biology. It is relevant to molecules that make up the structure of organs and cells which is the molecular anatomy. It describes carbon compounds and the reactions they undergo in living organisms. It also describes molecular physiology, which is the functions of molecules in carrying out the requirements of the cells and organs.

It mainly deals with the study of the structure and functions of the biomolecules such as carbohydrates, proteins, acids, and lipids. Hence, it is also called Molecular biology.

The primary branches of biochemistry are listed in this subsection.

It is also referred to as the roots of Biochemistry. It deals with the study of functions of the living systems. This field of biology explains all the interactions between DNA, proteins, and RNA and their synthesis.

Cell biology

Cell Biology deals with the structure and functions of cells in living organisms. It is also called Cytology. Cell biology primarily focuses on the study of cells of the eukaryotic organisms and their signalling pathways, rather than focussing on prokaryotes- the topics that will be covered under microbiology.

Metabolism

Metabolism is one of the most important processes taking place in all living things. It is nothing but the transformations or the series of activities that happens when food is converted into energy in a human body. One example of metabolism is the process of digestion.

Genetics

Genetics is a branch of biochemistry that deals with the study of genes, their variations and the heredity characteristics in living organisms.

The other branches include Animal and Plant Biochemistry, Biotechnology, Molecular Chemistry, Genetic engineering, Endocrinology, Pharmaceuticals, Neurochemistry, Nutrition, Environmental, Photosynthesis, Toxicology, etc.

Biochemistry is essential to understand the following concepts.

To learn more about biochemistry and other important branches of chemistry, such as physical chemistry, register with BYJUS now!

Read more:
What is Biochemistry? - Definition, History, Examples, Importance ...

Biochemistry

Biochemistry: Definition And Explanation – University of the People

Biochemistry is exciting and fascinating science, and this article will tell you everything youve been wanting to know about the field. Well give you the full biochemistry definition: the basics, the history, as well as the promising degrees and careers you can expect in the biochemists laboratory and beyond.

Biochemistry, or biological chemistry, is the branch of science that studies chemical and physicochemical processes within living organisms.

As a combination of biology and chemistry, biochemistry studies the chemical substances and processes which occur within the biology of the body or any living organisms.

Biochemists study large molecules such as carbohydrates and proteins in relation to metabolism and other important processes within the body. Other molecules that biochemists may study include enzymes and DNA. These types of molecules are important for understanding the complex processes which occur in all living organisms.

The term biochemistry was created by Carl Neuberg, a German chemist, in 1902. But the study itself has been around for over 400 years, essentially since the invention of the microscope in 1665 by Robert Hooke. The microscope made it possible to study cells.

In 1674, Anton van Leeuwenhoek was the first to observe live plant cells under the microscope, which opened up many more possibilities than the dead cells which were being observed up until then. Live cells allowed scientists to observe chemical processes that occurred within and between them.

In the 18th century, a notable discovery in the field was made by the French scientist, Antoine Lavoisier, who proposed the concept of photosynthesis, a process in which plants convert water, sunlight, and carbon dioxide into their nutrients. Lavoisier was also the first person to study cell respiration, which is the process of making the energy molecule in the cells mitochondria.

In the 20th century, DNA was acknowledged as the genetic material which made up the cell. This was established by James Watson and Francis Crick based on the research work of Rosalind Franklin.

Most recently, new technology continues to advance scientific studies in areas such as recombinant DNA, gene splicing, radioisotopic labeling, and electron microscopy.

A career in biochemistry is recommended for those who enjoy research, as it is generally a career in laboratory science. Most careers in the field require at least a bachelors degree, such as a position as a laboratory technician. Other positions, such as laboratory managers or principal investigators of research, will require a masters degree or a Ph.D.

Laboratory technicians engage in bench work and help perform experiments in the lab under the instruction of the principal investigators. Technicians need a bachelors degree in order to be qualified, but more education and research will allow for more independence in the lab.

Lab managers carry more responsibility in the laboratory and may conduct independent research under the guidance of the principal investigator.

Though a masters degree in the field will require an emphasis on research, a Ph.D. prepares biochemists for a career in independent research, principal investigators of research in laboratories, and lecturers in university.

There are also many industry positions available to biochemists. Biochemists may also work in governmental labs or for companies in agriculture, pharmaceuticals, public health, or biotechnology. Some biochemists may also work in services such as toxicology and forensics.

As one may imagine, a contender for biochemistry needs to have a good understanding of both biology and chemistry. Some universities may offer a specific biochemistry track, or students can begin their education by taking a bachelors degree in either biology or chemistry, with a minor in the other.

Biochemists also need to have a good grasp of mathematics and statistics in order to conduct research. As students advance in their studies, they will begin to hone in on their particular interests.

Similar studies include health sciences, which offer courses in biology, anatomy, biostatistics, and disease prevention. Universities such as the University of the People (UoPeople) offer associates and bachelors degrees in health science completely online and tuition-free. The university also offers potential certificate programs in health science that can give ones career the right boost.

As weve seen, the biochemistry definition includes a rich history and an exciting future for further discoveries. Since the invention of the microscope, biochemists have been investigating the complex, hidden world of cells and molecules.

Biochemistry is an exciting and constantly evolving field of science with an emphasis on research and laboratory technology. Different levels of education open up many opportunities for working in the field. If you have a passion for this science, then biochemistry may be a meaningful career choice for you.

More:
Biochemistry: Definition And Explanation - University of the People

Biochemistry

What is biochemistry? | New Scientist

Biochemistry is the study of the chemicals that make up life and how they behave. It seeks to explain how inanimate chemicals like carbohydrates and proteins can give rise to living organisms.

Biochemistry as a scientific discipline began in the 1700s and 1800s, with early studies of phenomena like fermentation and the discovery of the first enzyme. However, it blossomed in the 20th century, thanks in part to new techniques like X-ray crystallography that allowed biochemists to study the precise three-dimensional structures of molecules.

Perhaps the most famous biochemical molecule is deoxyribonucleic acid or DNA, the material that carries our genes. The structure of DNA was discovered in 1953 after a frantic (and at times disreputable) race. Famously, DNA is a double helix, made up of two strands that coil around each other. Each strand carries a sequence of letters, which are the basis of genes.

In the wake of this discovery, biochemists like Francis Crick realised that the information on DNA is used to make proteins, which are long chains of smaller molecules called amino acids. Proteins are the workhorses of living cells, doing everything from digesting food to pushing waste out of the cell. The long chains fold up into remarkably intricate structures, which are crucial to the proteins function.

However, before proteins can be made the information from DNA is first copied onto a third kind of molecule called RNA (ribonucleic acid), which is similar to DNA. RNA can also act as an enzyme, as proteins do. Its ability to perform so many tasks has led some biochemists to suggest that it played a key role in the origin of life on Earth, before DNA and protein arose.

Besides genetics, a second key area of biochemistry is metabolism: the processes by which organisms extract energy from their environment (for instance from food) and use it to move and build their bodies. Metabolism involves elaborate sequences of chemical reactions, some of which are cyclic so the original chemicals are recreated at the end. Complex chemicals are broken down into simpler ones to provide energy, and that energy is used to build new chemicals that the organism can use. Different organisms can have radically different metabolisms.

Biochemistry has also revealed that living cells have structural molecules. Some form the walls and membranes that surround cells and hold them together, while others link up into a kind of scaffolding called the cytoskeleton.

Other biochemical molecules are remarkable feats of evolutionary engineering. There are molecular motors and even rotating axles.

Biochemists are still discovering new things about natural organisms (although reports that some organisms can incorporate arsenic into their DNA appear to be false). They have also started designing new biochemistries, for example adding new letters to the DNA alphabet or swapping out some of the amino acids used to make proteins. This synthetic biology may lead to new medicines and other biotechnologies, as well as shedding light on the nature of life.

View post:
What is biochemistry? | New Scientist

Neuroscience

Department of Neuroscience School of Medicine and Public Health UW …

Neuroscience, which has had a longstanding tradition of excellence at the University of Wisconsin-Madison, has now entered an exciting new era by the creation of a Department of Neuroscience in the School of Medicine and Public Health. This department brings together research and teaching in wide ranging areas of neuroscience including the study of ion channels, synaptic transmission, neural development, sensory and cognitive physiology and neural circuits. The recent move of the department to a new research building, the second wing of the Wisconsin Institutes for Medical Research (WIMR) has further strengthened collaboration and innovation through shared interests, techniques, equipment and facilities. Proximity of WIMR to the Waisman Center and University Hospitals has also promoted collaborative efforts to apply the findings of basic research in neuroscience to the study and treatment of human disease.

Continue reading here:
Department of Neuroscience School of Medicine and Public Health UW ...

Human Behavior

Computers in Human Behavior Reports | Journal – ScienceDirect

Computers in Human Behavior Reports is an open access scholarly journal dedicated to examining human computer interactions and impact of computers on human behavior from diverse interdisciplinary angles. As a companion journal to Computers in Human Behavior (CHB), CHB Reports is a forum for both theoretical and practical implications of human-centered computing.

See original here:
Computers in Human Behavior Reports | Journal - ScienceDirect

Human Behavior

Dimensions of Human Behavior | SAGE Publications Inc

Case Studies

Preface

Acknowledgments

PART I A MULTIDIMENSIONAL APPROACH FOR MULTIFACETED SOCIAL WORK

Chapter 1. Human Behavior: A Multidimensional Approach

Elizabeth Hutchison, Cory Cummings, Leanne Charlesworth

Chapter 2. Theoretical Perspectives on Human Behavior

Stephen Gilson

Joseph Walsh

Joseph Walsh

PART II THE MULTIPLE DIMENSIONS OF PERSON

Chapter 3. The Biological Person

Michael Sheridan

Chapter 4. The Psychological Person: Cognition, Emotion, and Self

Elizabeth Hutchison, Linwood Cousins

Chapter 5. The Psychosocial Person: Relationships, Stress, and Coping

Chapter 6. The Spiritual Person

Elizabeth Cramer

PART III THE MULTIPLE DIMENSIONS OF ENVIRONMENT

Chapter 7. The Physical Environment

Chapter 8. Cultures

Chapter 9. Social Structure and Social Institutions: Global and National

Chapter 10. Families

Chapter 11. Small Groups

Chapter 12. Formal Organizations

Chapter 13. Communities

Read more here:
Dimensions of Human Behavior | SAGE Publications Inc

Immunology

Alberto Pugliese, M.D., Joins City of Hope as Director of The Wanek Family Project for Type 1 Diabetes and Chair of the Department of Diabetes…

CONTACTLetisia Marquez626-476-7593lemarquez@coh.org

LOS ANGELES Alberto Pugliese, M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute.

Pugliese has dedicated his 35-year career to studying type 1 diabetes from the preclinical period to the clinical diagnosis and, afterward, the setting of transplantation. His work has contributed to a greater understanding of genetic and cellular mechanisms that regulate immunological self-tolerance, specifically to molecules targeted in diabetes. Pugliese has provided seminal contributions in the field of type 1 diabetes genetics, immunology, pathology and clinical trials, and his work has been published in major international journals.

City of Hope is fortunate to welcome Dr. Pugliese as he shares our dedication to advancing type 1 diabetes research through scientific excellence, open collaboration and the training of new investigators, said Debbie C. Thurmond, Ph.D., director of the Riggs Institute and Ruth B. & Robert K. Lanman Chair in Gene Regulation & Drug Discovery Research.

Pugliese comes to City of Hope by way of the University of Miami, where he served as The J. Enloe and Eugenia J. Dodson Chair in Diabetes Research. He was also a tenured professor of medicine, Division of Diabetes Endocrinology and Metabolism, and a professor of microbiology and immunology, as well as serving as deputy director for Immune Tolerance Research at the Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami.

I am humbled and honored to join City of Hopes legendary diabetes research department that has made pivotal discoveries about diabetes for more than 50 years, Pugliese said. My team and I will continue and enhance that spirit of innovation and scientific pioneering, digging deeper into the secrets of genetics and the immune system, metabolism and diabetic complications.

A native of Italy, Pugliese earned his medical degree and postdoctoral research fellowship at the University of Palermo. He completed postdoctoral research fellowships at that university, and then trained with the late George Eisenbarth at the Joslin Diabetes Center at Harvard Medical School and the Barbara Davis Center for Childhood Diabetes at the University of Colorado Health Sciences Center.

Pugliese is a champion of collaboration and team-science approaches, which has been recognized by the Helmsley Charitable Trust with the George S. Eisenbarth nPOD Award for Team Science. He has served on research grant review committees of the National Institutes of Health (NIH), the JDRF and other funding organizations internationally. He also served as chair of the American Diabetes Associations Grant Review Panel. He has been a steering committee member of the Type 1 Diabetes TrialNet, a clinical trial network funded by the NIH, under which auspices he has chaired several committees and initiatives.

Pugliese is also executive co-director of the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD), a collaborative project that recovers tissues from organ donors with type 1 diabetes and distributes samples to investigators worldwide to support a comprehensive understanding of the disease.

# # #

About City of HopeCity of Hope's mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. As an independent, National Cancer Institute-designated comprehensive cancer center, City of Hope brings a uniquely integrated model to patients, spanning cancer care, research and development, academics and training, and innovation initiatives. Research and technology developed at City of Hope has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. A leader in bone marrow transplantation and immunotherapy, such as CAR T cell therapy, City of Hopes personalized treatment protocols help advance cancer care throughout the world.With a goal of expanding access to the latest discoveries and leading-edge care to more patients, families and communities, City of Hopes growing national system includes its main Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California and Cancer Treatment Centers of America. City of Hopes affiliated family of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, Instagram and LinkedIn.

Read more from the original source:
Alberto Pugliese, M.D., Joins City of Hope as Director of The Wanek Family Project for Type 1 Diabetes and Chair of the Department of Diabetes...

Immunology

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board – StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO & BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering platform to develop next-generation multifunctional cytokine-based immunotherapies, today announced the formation of a Scientific Advisory Board ("SAB") comprised of world-renowned experts in immuno-oncology basic, translational and clinical research.

"Bright Peak is truly privileged and excited to have such an accomplished and dedicated group of scientific and clinical experts to advise on our discovery and clinical development programs," said Fredrik Wiklund, Chief Executive Officer of Bright Peak. "Their combined resume includes some of the most groundbreaking discoveries in immuno-oncology, from basic biology through clinical investigation." Jon Wigginton, M.D., President of Research and Development at Bright Peak added, "We are honored to welcome this outstanding group of investigators to the Bright Peak SAB and look forward to leveraging their expertise in our shared mission to develop transformative precision immunotherapies that address significant unmet needs for patients with cancer."

The members of Bright Peak's Scientific Advisory Board include:

Gordon Freeman, Ph.D., Professor of Medicine at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, is renowned for discovering the PD-L1 and PD-L2 proteins. Dr. Freeman showed that PD-L1 and PD-L2 bound to PD-1 to turn off the immune response and that blockade of PD-L1/PD-1 enhanced immune responses. He further showed that PD-L1 is highly expressed on many tumors and allows these tumors to resist immune attack. Dr. Freemans work led directly to the development of a successful strategy for cancer immunotherapy - blocking the PD-1-ligand interaction. Dr. Freeman has published over 400 scientific papers and holds over 90 US patents on immunotherapies. He was elected to the National Academy of Sciences and the National Academy of Inventors, is a Fellow of the AACR and SITC Academies, and has received numerous awards, including the William B. Coley Award for Distinguished Research in Tumor Immunology, the Warren Alpert Foundation Prize, and the Richard Smalley, MD, Memorial Award. Dr. Freeman received his Ph.D. degree in Microbiology and Molecular Genetics from Harvard University.

Thomas Gajewski, M.D., Ph.D., is the AbbVie Foundation Professor in Cancer Immunotherapy, leader of the Immunology and Cancer program, and Director of Melanoma Oncology at the University of Chicago. Dr. Gajewski's notable discoveries includethe identification of the STING pathway and how it stimulates the body's innate immune system to attack cancer, downstream pathways including Wnt/-catenin that enable tumors to evade immune responses, and the connection between the immune system's response to cancer and the gut microbiota. An author of more than 250 manuscripts, Dr. Gajewski is past president of SITC, a founding editor of the Journal for Immunotherapy of Cancer, past chair of the Cancer Immunopathology and Immunotherapy grant review study section at the NIH, has served on the program committees for ASCO and AACR, a grant reviewer for the Melanoma Research Alliance and Cancer Research Institute, and editor for Cancer Research. Among numerous honors, Dr. Gajewski has received theWilliam B. Coley Awardfor Distinguished Research in Tumor Immunology, the ESMO award in Immuno-oncology, the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, and Distinguished Professor designation at the University of Chicago. He holds a B.S., Ph.D. in Immunology, and M.D. degrees from the University of Chicago where he also completed Internal Medicine Residency and Hematology/Oncology Fellowship.

Jason Luke, M.D., is the Director of the Immunotherapy and Drug Development Center at UPMC Hillman Cancer Center and Associate Professor at the University of Pittsburgh. Dr. Luke is an internationally recognized investigator in translational immuno-oncology, early phase drug development and the clinical management of cutaneous malignancies. Dr. Luke has designed and led two practice-changing studies in melanoma - the combination of anti-PD1 + low-dose anti-CTLA4 Ab in PD1 refractory disease, and establishing the role for, and FDA/EMA approval of, adjuvant anti-PD1 for stage IIB/C melanoma. More generally, Dr Luke has been a lead investigator for many first-in-human trials of novel immunotherapies and a major contributor toward the investigation of radiation, the microbiome and bioinformatic approaches in relation to cancer immunotherapy. Dr. Luke is an At Large member of the Board of Directors for SITC and has held leadership roles in SMR, AACR & ASCO. He is a member of the NCI Investigational Drug Steering Committee and the Immunotherapy Task Force co-Chair. He has received numerous awards including the Melanoma Research Foundation Humanitarian Award, ASCO Merit Award, and the NCI Cancer Clinical Investigator Team Leadership Award. Dr. Luke received an M.D. from Rosalind Franklin University of Medicine and Science/Chicago Medical School, completed Internal Medicine Residency at Boston University Medical Center and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center.

Ignacio Melero, M.D., Ph.D., is Co-Director of the Department of Immunology and Immunotherapy and Professor of Immunology at the Clinica Universidad de Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra, Spain. Dr. Melero is an international leader in translational tumor immunotherapy research who focuses on cytokine gene therapy, immune-stimulatory monoclonal antibodies, and cell therapy for cancer. Dr. Melero is renowned for seminal discoveries in the function of NK cell inhibitory receptors (KIRs) and T-cell co-stimulation via CD137 (4-1BB). Dr. Melero has served as principal investigator in numerous clinical trials of cancer immunotherapy and has won multiple awards including the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a Cancer Research Institute research award. Dr. Melero earned an M.D. degree from the University of Navarra School of Medicine, completed Residency in Immunology at the Hospital Universitario de la Princesa (Madrid) and earned a Ph.D. in Immunology at La Princesa Hospital, Autonomous University of Madrid, Spain.

Anthony Tolcher, M.D., is founder and CEO of NEXT Oncology, one of the most successful and respected Phase 1 programs in oncology research. Prior to founding NEXT Oncology, Dr. Tolcher was President and Co-Founder of START LLC, one of the world's largest Clinical Phase I and early drug development operations in cancer medicine. Dr. Tolcher is a medical oncologist with over 25 years' experience in early drug development and clinical trials and has been involved in more than 21 of the initial Phase 1 studies of new oncology agents that subsequently were FDA approved, including PD-(L)1 inhibitors, antibody-drug conjugates, anti-tumor-associated antigen antibodies, and numerous targeted therapies, and he is currently the principal investigator of over 20 Phase 1 studies. He has over 130 peerreviewed publications in scientific journals and has chaired the Developmental Therapeutics Review Committee for ASCO. Dr. Tolcher obtained his M.D. degree from the University of British Columbia and then completed Internal Medicine Residency at the University of Toronto, Oncology Fellowship at the University of British Columbia and a research fellowship at the NCI, Bethesda.

About Bright Peak TherapeuticsBright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We are rapidly advancing a robust portfolio of next-generation, multi-functional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:[emailprotected]

The rest is here:
Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board - StreetInsider.com

Immunology

Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases – Yahoo Finance

Gritstone bio

-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstones samRNA vaccine candidates against SARS-CoV-2 --

EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced that it will host a webinar on October 25, 2022 to present data from its CORAL program and discuss the application of its self-amplifying mRNA (samRNA) vaccine platform for infectious diseases. During the webinar, lead investigators will present data from the ongoing Phase 1 CORAL-BOOST and CORAL-CEPI trials which are evaluating the companys samRNA vaccine candidates against SARS-CoV-2. Following the data presentations, Lawrence Larry Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, will speak to the potential application of samRNA vaccines against infectious diseases.

Presenters and Content

Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme, will present data from CORAL-BOOST. This presentation will expand on study data being presenting at IDWeek 2022.

Professor Shabir Madhi, Dean of the Faculty of Health Sciences, Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa, will present the interim data from CORAL-CEPI. This presentation will include data on virus-nave subjects.

Larry Corey, M.D., virology, immunology and vaccine development expert, former President & Director of Fred Hutchinson Cancer Center (Fred Hutch) and Board Member of Gritstone bio, will speak to the landscape and broad potential application of samRNA.

Company management will also provide an overview of self-amplifying mRNA (samRNA) as a novel vaccine platform for the prevention and treatment of infectious diseases.

The presentations will be followed by a Q&A session.

Webinar DetailsDate and time: 8:00 9:00am ET on Tuesday, October 25Link: To register for the webinar, please click here

Story continues

A replay of the webinar will be accessible for 30 days following the event on the events page of the companys website: https://ir.gritstonebio.com/investors/events.

About the CORAL ProgramGritstones CORAL program is evaluating the companys infectious disease approach, which is designed to drive both B cell and T cell immunity using a self-amplifying mRNA (samRNA) vector, against SARS-CoV-2. The program currently includes three ongoing Phase 1 trials: CORAL-BOOST, which is evaluating one construct in a boost setting (following primary series of currently-approved COVID-19 vaccines); CORAL-CEPI, which is evaluating multiple constructs in virus-nave, convalescent, and HIV+ subjects in South Africa; and CORAL-NIH, which is being run by the National Institute of Allergy and Infectious Disease (NIAID), is evaluating multiple constructs in previously vaccinated healthy volunteers. The program serves as proof-of-concept for the application of Gritstones platform against coronaviruses and other infectious diseases and is supported by theBill & Melinda Gates Foundation,NIAID and theCoalition for Epidemic Preparedness Innovations(CEPI).

About Gritstone bioGritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the worlds most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. http://www.gritstonebio.com

Gritstone Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstones therapeutic programs; the advancements in Gritstones ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstones research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstones programs clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstones ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstones most recent Annual Report on Form 10-K filed on March 10, 2022, as well as Gritstones Quarterly Reports on Form 10-Q filed on May 5, 2022 and August 4, 2022 and any current and periodic reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof. Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone ContactsInvestors:George E. MacDougallDirector, Investor Relations & Corporate CommunicationsGritstone bioir@gritstone.com

Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com

Read the original here:
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases - Yahoo Finance